EWA
NKTR icon

Evolution Wealth Advisors’s Nektar Therapeutics NKTR Stock Holding History

Evolution Wealth Advisors’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2
Closed – – 668
2019
Q3 		$0 Sell
2
-15
-88% -$5.5K ﹤0.01% 557
2019
Q2 		$9K Buy
+17
New +$8.52K ﹤0.01% 188

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Evolution Wealth Advisors's NKTR Position: Q4 2019 in Review

Evolution Wealth Advisors sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 2 shares.

Evolution Wealth Advisors first reported a position in NKTR in Q2 2019 and held it in 2 quarters. The position peaked at $9K in Q2 2019. 280 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Evolution Wealth Advisors reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Evolution Wealth Advisors sold 2 Nektar Therapeutics shares in Q4 2019.
  • Evolution Wealth Advisors first reported a position in Nektar Therapeutics in Q2 2019 and held it in 2 quarters.
  • Evolution Wealth Advisors's Nektar Therapeutics position peaked at $9K in Q2 2019.
  • 280 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Evolution Wealth Advisors's 13F filing for Q4 2019, filed 3 Feb 2020.